ROS1 and non-small cell lung carcinoma: However, given the relatively long survival of ROS1-positive NSCLC patients, a more recent ROS1 inhibitor generation is currently under investigation, with an encouraging improvement in the control of central nervous system (CNS) metastasis and a demonstrated efficacy in both pretreated and naïve crizotinib patients [9].